← Back to Clinical Trials
Recruiting NCT07433985

NCT07433985 California MEPS Hub

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07433985
Status Recruiting
Phase
Sponsor University of California, Los Angeles
Condition HIV Prevention
Study Type INTERVENTIONAL
Enrollment 318 participants
Start Date 2025-12-01
Primary Completion 2029-07-31

Trial Parameters

Condition HIV Prevention
Sponsor University of California, Los Angeles
Study Type INTERVENTIONAL
Phase N/A
Enrollment 318
Sex MALE
Min Age 18 Years
Max Age 59 Years
Start Date 2025-12-01
Completion 2029-07-31
Interventions
Mobile Enhanced Prevention Support (MEPS)Control

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The California Hub for HIV/SUD Prevention Research with Reentry Populations addresses the question: "Can the evidence-based MEPS intervention be adapted and implemented at a range of organizations to effectively serve a wider range of clients?" The Mobile Enhanced Prevention Support (MEPS) intervention was originally implemented in Los Angeles County and was proven successful in promoting biomedical HIV prevention (PrEP) uptake and preventative screenings in people who used drugs who recently left incarceration. MEPS is an evidence-based intervention for people with substance use disorders (SUD) that incorporates a client-centered planning session, including trained peer mentors, service utilization incentives, and a mobile application (GeoPass). The study includes a randomized controlled trial (RCT) across three community partners located in Riverside and Alameda Counties. At least 300 people will be enrolled in these three counties; the first 200 will be randomized to either receive the intervention or usual care, with the final 100 all receiving the intervention. The primary implementation outcome for the study involves using an implementation science framework and assessment tools to examine MEPS's implementation. Key outcomes include how well the implementation strategies used support intervention enrollment and retention, integration with existing services in each partnering community agency, and perceived intervention acceptability, feasibility, appropriateness, and maintenance at 6- and 12-months. The primary effectiveness outcome for the study is an increase in HIV testing, PrEP uptake and adherence, and SUD service utilization at 6 months and 12 months in the MEPS compared to the usual care group. Secondary effectiveness outcomes include frequency of service use for SUDs, hepatitis C virus testing, and linkage to care for those who test positive for HIV or hepatitis C.

Eligibility Criteria

Inclusion Criteria: RCT Participants * Assigned male at birth * Ages 18 - 59 * Was released from incarceration in the previous 12 months (incarceration is defined as a stay in jail, prison, or detention centers for over 24 hours) * Reports an SUD diagnosis or seeking SUD services at any time in the 24 months prior to enrollment * During the 24 months prior to enrollment, either: 1. Reports intercourse with a person assigned male at birth 2. Reports injection drug use * Has not received an HIV diagnosis (based on self-report) * Possesses a smartphone or plans to obtain one * Plans to reside within designated jurisdictions (counties) for the 9 months following enrollment CBO and agency staff participating in implementation surveys or interviews * \>=18 years of age * Employed at a study site or otherwise involved with intervention implementation and/or maintenance OR works at an agency in the counties where the study is taking place (Los Angeles, Riverside, San Bernardino, and Alameda co

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology